Company / Cash & Equivalents
MoonLake Immunotherapeutics Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$334.5M
FY2025
5-year range
$8.0M / $451.2M
FY2021-FY2025
Trend
+85.4%
vs FY2024
Sector context
#58 of 207
Health Care
What the data says
At $335M, MoonLake Immunotherapeutics's cash & equivalents ranks #58 of 207 in the Health Care sector. Declined from $451M to $335M over the past 2 years.
Based on SEC 10-K filings.
$335M in FY2025 with a 5-year CAGR of +201.8%.
Declined from $451M to $335M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +103.8%
- 5-Year CAGR
- +201.8%
- 10-Year CAGR
- -
Sector benchmark
#58 of 207 in Health CareTop 28% of 207This company $334.5M Sector average $669.5M
▼
-50.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +201.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 85.4% year-over-year.
- Ranks #58 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $334.5M | +85.4% |
| FY2024 | $180.4M | -60.0% |
| FY2023 | $451.2M | +1042.0% |
| FY2022 | $39.5M | +391.4% |
| FY2021 | $8.0M | +501.7% |
| FY2020 | $1.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026